Children’s Hospital of Philadelphia – Childhood Metastatic Pheochromocytoma

Access Program Information

Metaiodobenzylguanidine (MIBG) is a substance that is taken up by neuroblastoma or
pheochromocytoma/paraganglioma tumor cells. MIBG is combined with radioactive iodine (131 I)
in the laboratory to form a radioactive compound 131 I-MIBG. This radioactive compound
delivers radiation specifically to the cancer cells and causes them to die.

The purpose of this research protocol is to provides a mechanism to deliver MIBG therapy
when clinically indicated, but also to provide a mechanism to continue to collect efficacy
and toxicity data that will be provided.